Welcome to Cross-Canada Paediatric - Respiratory Residency Rounds
PRINT PAGE

CONTINUED from page 11


DIAGNOSIS, CONTINUED

b) Serological Diagnosis:
General: Eosinophilia
- frequently absent
- protection of lung cysts from host immune response

ELISA:
- not specific (cross-reactivity with helminths other than Echinococcus, and in non-infectious conditions such as malignancy and autoimmune diseases)
- positive in 90% with liver disease
- positive in 50% with lung cysts only

TREATMENT

a) Surgical:
- lung-preserving resection is treatment of choice
- very high cure rate
- several techniques described
- intraoperative risk of spillage causing disseminated disease likely overstated, based upon a large case series that found that even cysts that ruptured pre-op had minimal recurrence

b) Medical:
- benzimidazole compounds (mebendazole and albendazole)
- may be sufficient for small pulmonary cysts
- also indicated if surgery not feasible
- no indication for pre-op treatment
- WHO recommendations are for treatment of inoperable disease or incomplete surgery, or to prevent secondary echinococcus after spontaneous or traumatic rupture
- some advocate post-op treatment, especially if spillage
- minimal evidence

Main risks:
- potential teratogenicity (in lab animals)

Side effects are usually mild:
- GI disturbance, transaminase elevation, hair loss, sleeplessness, leukopenia

PROGNOSIS AND OUTCOME

- pediatric series (n=33) from Austria
- no operative deaths
- 2 patients had recurrence (mean f/u 4.8 yrs)
- large (n=405) series from Turkey
- 4 had recurrent cysts (3 had ruptured before surgery)
- f/u range 16 to 58 months
- prognosis generally excellent


Next page

1 2 3 4 5 6 7 8 9 10 11 12 13